0001683168-25-002420.txt : 20250410 0001683168-25-002420.hdr.sgml : 20250410 20250410172844 ACCESSION NUMBER: 0001683168-25-002420 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250410 DATE AS OF CHANGE: 20250410 EFFECTIVENESS DATE: 20250410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACTUATE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001652935 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 473044785 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-543404 FILM NUMBER: 25829330 BUSINESS ADDRESS: STREET 1: 1751 RIVER RUN STREET 2: SUITE 400 CITY: FORT WORTH STATE: TX ZIP: 76107 BUSINESS PHONE: 847-986-4190 MAIL ADDRESS: STREET 1: 1751 RIVER RUN STREET 2: SUITE 400 CITY: FORT WORTH STATE: TX ZIP: 76107 FORMER COMPANY: FORMER CONFORMED NAME: Apotheca Therapeutics, Inc. DATE OF NAME CHANGE: 20150911 D 1 primary_doc.xml X0708 D LIVE 0001652935 ACTUATE THERAPEUTICS, INC. 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 817-887-8455 DELAWARE None Apotheca Therapeutics, Inc. Corporation true Daniel Schmitt 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Executive Officer Director Paul Lytle 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Executive Officer Aaron G.L. Fletcher 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Director Jason Keyes 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Director Amy Ronneberg 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Director Roger Sawhney 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Director Todd Thomson 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Director Daniel Zabrowski 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Director Andrew Mazar 1751 River Run Suite 400 Fort Worth TX TEXAS 76107 Executive Officer Pharmaceuticals Decline to Disclose 06b false true true true false 0 50000000 0 50000000 Offering is a committed equity facility under which the issuer has the right, in its sole discretion, to sell to the investor up to an aggregate of $50,000,000 of the issuer's common stock from time to time. false 1 0 0 0 false ACTUATE THERAPEUTICS, INC. /s/ Paul Lytle Paul Lytle Chief Financial Officer 2025-04-10